Our
Ikigai

Our reason for being

what we love

what the
world needs

what is
economically
sustainable

what we
are good at

Ikigai compounds two Japanese words: iki meaning «life» and gai meaning «result». Hence, Ikigai is a Japanese concept that means «a reason for being». The word refers to having a meaningful direction: our purpose in life.

Having a clear and defined ikigai gives satisfaction, passion, happiness, and meaning to life. At Towa our Ikigai is clear…

At Towa International, we contribute to people’s health. We are dedicated to genuine smiles

We want to be an active player in the national sustainability health systems and provide high-quality and valued medicines through our R&D center, as well as the international presence and strategic alliances, to patients around the world.

Our
commitments

1

Quality, safety and efficacy of our medicines.

2

Health and quality of life of patients.

3

Sustainability of public health systems and health promotion.

4

Good governance and ethical and responsible practices.

5

Transparency and creation of valuable relationships with our stakeholders.

6

Reduction of the environmental impact of our activities.

Our
people 

We have a shared vision

As part of Towa, we are health ambassadors, starting with ourselves and our surroundings. #WeAreCommittedToHealth 

We are more than 900 professionals across 4 countries: Spain, Italy, Portugal, and the United States of America.

Towa’s human team is behind the success of our high-quality products and services.

They are our key element

Real people who internalize the corporate philosophy as part of their DNA and work every day to contribute directly to the purpose of our company.

We want to be recognized for caring for people’s health, starting with our own, and for flexibility.

We want to be the company where people decide to stay because of our purpose and our well-being.

We have two axes of the value proposition to our employees and part of the culture that as Towa we want to promote.

Health__________Flexibility

We are going to work intensely to advance with measures in both areas so that all of us can balance our personal lives with the responsibilities of our work. This will improve the efficiency of our organization and our health and well-being.

From Towa
to the World

Our Journey begins in 1951

Towa Pharmaceutical was founded in Osaka, Japan as a wholesale and brokerage of pharmaceutical raw materials.

Towa Group contributes to people’s health by creating superior products and services.

Through our corporate activities, we aim to be a company that is valued and needed by patients, medical professionals, local communities, and others.

In 2020 Towa became international by adding the Pensa Pharma business, a well-established patent medicine platform with a commercial presence in the US and the EU and R&D and manufacturing capabilities.

Through this internationalization milestone, Towa International headquarters were established in Barcelona, Spain.

At Towa International, we work to research, develop and market generic and value-added medicines (VAM) that contribute to improving the health of patients. In turn, they allow greater availability and better management of treatments for health professionals and support the sustainability of health systems in more than 30 countries in which we operate.

#FromTowaToTheWorld

Our story together

TOWA
PHARMACEUTICAL

TOWA
INTERNATIONAL

1951

Towa Pharmaceutical was founded.

1989

Pensa originates from PPI expertise and a non-infringement formulation of Omeprazole

1992

Contruction of Martorelles (Barcelona) manufacturing and R&D facilities

1996

Mr. Itsuro Yoshida became the president

1998

Creation of B2B business 

1998

Osaka Research Center and Osaka Distribution Center are constructed at Ichiban-cho, Kadoma, Osaka

1999

Launch of Omeprazole 

2004

Towa was listed on stock exchange 

2006

Pensa Pharma Foundation

2007

Start of the internationalisation phaseExpanded Pensa into Italy with the purchase of 20 additional products. 

2008

Built pilot plant and expanded R&D capabilities. Entered Portugal through the acquisition of toLife, adding 30 additional products to Pensa’s portfolio 

2009

Entered U.S.A with acquisition of Breckenridge. Entered Sweeden 

2010

Towa purchases Daichi Kasei Co., Ltd., and makes it subsidiary 

2012

Entered Germany 

2016

Established Greencaps Pharmaceutical Co., Ltd.

2020

Foundation of Towa Pharma International Holding

2020

Internationalisation

2021

Expansion manufacturing facilities 

2021

Towa purchases Protosera Inc. and makes it subsidiary  

2022

Internalization process. Entering South America and Middle East though licenses 

2022

Towa purchases Sunsho Pharmaceutical Co., Ltd. and makes it subsidiary

Towa
Pharmaceutical

Towa Presence in Japan

We ensure to cover all the phases
of our value chain in our products

Active Pharmaceutical Ingredients (APIs)

Research and Development of Finished Dosage Forms (FDFs)

Regulatory Affairs and Quality Control

Manufacturing and Stable product supply

Marketing and distribution

Towa Pharmaceutical
In numbers

0nd

generic medicines company ranking in Japan

+0B€

in sales

+0M€

R&D investment

+0

therapeutic areas

+0

employees

+0

products

+0B€

tablets per year

0

Research centers 

0

Manufacturing plant

Entering new
health-related business

As one of our challenges, we aim for creating a future that provides full coverage of medical expenses to care for pre-symptomatic disease and prevention for society with a long and healthy life expectancy.

In line with our vision of contributing to people’s health, we will work to create new health-related businesses that are suited to the new medical system, while acquiring new techniques and integrating them with completely new knowledge and technologies.

Specifically, we will help build an infrastructure to create ideal local communities, and contribute to extending healthy life expectancy by providing necessary health promotion services to people in need of them.

Among our key measures, we will be launching testing services for determining disease risks, expanding the KENTO Healthcare Science Center, which opened in 2019 to conduct joint research with the National Cerebral and Cardiovascular Center to extend healthy life expectancy, and collecting/ utilizing information obtained from testing to provide appropriate health-related services.

Key measures

  • Building a foundation for extending healthy life expectancy by utilizing key data
  • Contributing to the Comprehensive Community Care System
  • Further enhancing the lineup of products and services to maintain and improve health
  • Entering disease risk testing service business
  • Creating synergies with existing businesses

Ethics &
Compliance

At Towa, we promote a culture of ethics and integrity. We recognize the importance of open communication when it comes to addressing concerns related to the conduct of individuals.

We provide dedicated channels to report any irregularities, ensuring effective and efficient communication.

Through our Ethics & Compliance communication channel, you can raise any concerns you may have, knowing that your identity will remain confidential. Rest assured that every report received will be treated with the utmost seriousness and addressed promptly.

Thank you for your dedication to maintaining our business ethics. Your active participation makes a significant difference in fostering a positive and respectful work environment.

You can report your concerns here.